Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive‐stage small cell lung cancer: Two case reports

Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive‐stage small cell lung cancer: Two case reports

Abstract The IMpower133 regimen, composed of atezolizumab/etoposide (VP‐16)/carboplatin (CBDCA), is the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC). However, the safety and efficacy of triplet therapy in patients receiving dialysis have not been sufficiently ev...

Full description

Bibliographic Details
Main Authors: Naokazu Watari, Kakuhiro Yamaguchi, Takeshi Masuda, Noriaki Ito, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:Thoracic Cancer
Subjects:
adverse effects
dialysis
small cell lung carcinoma
Online Access:https://doi.org/10.1111/1759-7714.14166

Internet

https://doi.org/10.1111/1759-7714.14166

Similar Items